Malaria,Falciparum Clinical Trial
Official title:
A Randomized, Open-Label Exploratory Study To Determine The Efficacy Of Different Treatment Regimens Of Pyramax® (Pyronaridine-Artesunate) In Asymptomatic Carriers Of Plasmodium Falciparum Monoinfections
Verified date | September 2019 |
Source | Shin Poong Pharmaceutical Co. Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will assess the efficacy of Pyramax administered for three-day, two-day or one
day, in clearing a P. falciparum infection in asymptomatic carriers.
.
Status | Active, not recruiting |
Enrollment | 300 |
Est. completion date | October 2019 |
Est. primary completion date | October 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 5 Years and older |
Eligibility |
Inclusion Criteria: 1. Evidence of asymptomatic infection with Plasmodium falciparum monoinfection on thin and thick blood smears with parasite density between 20/µL and 50,000/µL 2. Absence of any clinical symptoms of malaria at the time of enrolment and within 72 hours before enrolment 3. Age >5 years old and >20 kg body weight 4. Ability to swallow oral medication 5. Evidence of a personally signed and dated Informed Consent document indicating that the participant (or a legally acceptable representative if a participant is <18 years of age) has been informed of all pertinent aspects of the study and that all questions by the participant have been sufficiently answered. Assent will be obtained from participants <18 years of age as required by national regulations. 6. Participants who are willing to and are able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion Criteria: 1. Haemoglobin <7 g/dL (measured at screening) 2. History of having received any antimalarial treatment (alone or in combination) during the following periods before screening: 1. Piperaquine, mefloquine, naphthoquine or sulfadoxine-pyrimethamine within 6 weeks prior to screening 2. Amodiaquine, chloroquine within 4 weeks prior to screening 3. Any artemisinin derivative (artesunate, artemether or dihydroartemisinin), quinine, lumefantrine or any other anti-malarial treatment or antibiotic with antimalarial activity (including cotrimoxazole, tetracyclines, quinolones and fluoroquinolones and azithromycin) within 14 days prior to screening 3. Any herbal products or traditional medicines during the 7 days prior to screening (if spontaneously reported by the patient) 4. Known allergy to the study drugs (pyronaridine and/or any artemisinin derivatives) 5. Positive urinary pregnancy test for women of reproductive age 6. Lactating women 7. Evidence of severe malnutrition 8. Participation in other studies within 30 days before the current study begins and/or during study participation 9. Inability to comprehend and/or unwillingness to follow the study protocol 10. Previously randomized in this study 11. Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study. Examples would include but not limited to: 1. Immunological disorders (including known seropositive HIV antibody), 2. Severe psychiatric disorders (active depression, recent history of depression, generalised anxiety, psychosis, schizophrenia or other major psychiatric disorders) and major medical disorders related to cardiovascular, respiratory (including active tuberculosis), renal, gastrointestinal, endocrine, infectious, malignancy, neurological (including auditory) and history of convulsions or other abnormality (including recent head trauma), 3. Clinical signs or symptoms of hepatic injury (such as nausea, abdominal pain associated with jaundice) or known severe liver disease (i.e. decompensated cirrhosis, Child-Pugh stage 3 or 4) 12. Participant the Investigator considers at particular risk of receiving an anti-malarial or of participating in the study |
Country | Name | City | State |
---|---|---|---|
Gambia | MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, | Fajara, | Banjul, |
Zambia | Tropical Diseases Research Centre | Ndola |
Lead Sponsor | Collaborator |
---|---|
Shin Poong Pharmaceutical Co. Ltd. | Medicines for Malaria Venture |
Gambia, Zambia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Parasite free by qPCR quantification | To estimate the proportion of participants who are parasite free by qPCR quantification. | 63 days | |
Other | PCR-adjusted APR by qPCR | To estimate PCR-adjusted APR by qPCR.To estimate PCR-unadjusted APR by qPCR. To estimate the rate of recurrent infections, recrudescences and new infections by qPCR until Day 63 (post first dose) by KM analysis. | 63 days | |
Other | Percentage change in gametocytaemia. | In participants with positive detection of gametocytes by reverse transcriptase (RT)-PCR at baseline, to evaluate percentage reduction in gametocytaemia. | 63 days | |
Other | AUC of gametocytaemia by RT-PCR | To estimate area under the curve (AUC) up to Day 14 of gametocytaemia by RT-PCR, in participants with positive RT-PCR at baseline and separately in participants with negative RT-PCR at baseline | 14 days | |
Other | Relationship between artesunate and pyronaridine concentration and efficacy | To explore the relationship between artesunate and pyronaridine concentration and efficacy (PCR-adjusted APR at Day 28, based on slide assessment by microscopy) | 28 days | |
Primary | PCR-adjusted APR at Day 28 (based on slide assessment by microscopy) | To assess the efficacy of each dosing regimen PCR-adjusted Adequate parasitological response (APR) at Day 28 | Day 28 | |
Secondary | PCR-adjusted APR | To assess the efficacy of each dosing regimen PCR-adjusted APR at Day 63 | 63 days | |
Secondary | PCR-unadjusted APR | To assess the efficacy of each dosing regimen PCR-unadjusted APR at Day 63 | 63 days | |
Secondary | Rate of recurrent infections, recrudescence and new infections | To assess the efficacy of each dosing regimen on rate of recurrent infections, recrudescence and new infections | 63 days | |
Secondary | Proportion of parasite free participants | Proportion of participants who are parasite free by 4-8 hours, Day 1, Day 2 and Day 3 post first dosing | 4 days | |
Secondary | Gametocyte incidence | The area under the curve (AUC) up to Day 14 (post first dose) of gametocytes in participants with gametocytes at baseline, and separately in participants without gametocytes at baseline | 14 days | |
Secondary | Adverse Events | Number (%) of patients and number of events with: TEAEs, serious TEAEs, study drug related TEAEs, study drug related serious TEAEs, malaria-related TEAEs, malaria-related serious TEAEs Number (%) of patients with TEAEs and drug-related TEAEs by maximum severity, based on Grade 1 to Grade 5 (CTCAE V4.03) severity grading Adverse events will be coded by MedDRA primary system organ class and preferred term. Hepatotoxicity related TEAEs o The number and percentage of patients with hepatotoxicity related TEAEs, based on the Standard MedDRA Query (SMQ) narrow search "Drug-related hepatic disorders" will be summarised and clinical biochemistry parameters |
63 days | |
Secondary | Clinical laboratory data - Haematology | Haemoglobin, haematocrit, erythrocytes, platelets, white blood cells, neutrophils, lymphocytes, monocytes, eosinophils, basophils will be summarised over time, as absolute values and changes from baseline with the number of observations, mean, standard deviation, median, quartiles, minimum and maximum. SI units will be used to summarise the data. | 63 days | |
Secondary | Clinical laboratory data - Biochemistry | Total and conjugated bilirubin will be summarised over time, as absolute values and changes from baseline with the number of observations, mean, standard deviation, median, quartiles, minimum and maximum. SI units will be used to summarise the data. | 63 days | |
Secondary | Clinical laboratory data - Liver Enzymes | Alanine aminotransaminase (ALT), Aspartate aminotransaminase (AST), Alkaline Phosphatase will be summarised over time, as absolute values and changes from baseline with the number of observations, mean, standard deviation, median, quartiles, minimum and maximum. IU/L units will be used to summarise the data | 63 days | |
Secondary | Clinical laboratory data - Liver Enzyme Elevations | The number (%) of participants with liver enzyme elevations after first drug administration as defined below will be summarised. ALT or AST > 3 x Upper Limit of Normal (ULN) ALT or AST > 5 x ULN ALT or AST > 8 x ULN ALT or AST > 3 x ULN and bilirubin > 2 x ULN at the same time point (when conjugated bilirubin fraction is missing) ALT or AST > 3 x ULN and bilirubin > 2 x ULN, together with a conjugated bilirubin fraction >35% (Potential Hy's law cases), at the same time point |
63 days | |
Secondary | Vital signs - Blood pressure | Supine systolic and diastolic blood pressure (mm Hg) absolute values and changes from baseline will be summarised by time point with the number of observations, mean, standard deviation, median, minimum and maximum, and quartiles | 63 days | |
Secondary | Vital signs - Pulse rate | Pulse rate (bpm) absolute values and changes from baseline will be summarised by time point with the number of observations, mean, standard deviation, median, minimum and maximum, and quartiles | 63 days | |
Secondary | Vital signs - Temperature | Temperature (degrees Celsius) absolute values and changes from baseline will be summarised by time point with the number of observations, mean, standard deviation, median, minimum and maximum, and quartiles | 63 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04130282 -
VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine
|
Phase 1 | |
Completed |
NCT04049916 -
Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04079621 -
Short Course Radical Cure of P. Vivax Malaria in Nepal
|
Phase 4 | |
Completed |
NCT05135273 -
Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali
|
Phase 1 | |
Not yet recruiting |
NCT06083688 -
Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi
|
Phase 4 | |
Recruiting |
NCT03511443 -
Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections
|
N/A | |
Completed |
NCT05550909 -
Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali
|
Phase 2 | |
Recruiting |
NCT05306067 -
Plasmodium Falciparum Genomic Intelligence in Mozambique
|
||
Completed |
NCT05081089 -
Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali
|
Phase 2 | |
Recruiting |
NCT05150808 -
Vectron T500 (Broflanilide 50WP) for IRS in Tanzania Tanzania
|
Phase 3 | |
Recruiting |
NCT05757167 -
Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics
|
Phase 4 | |
Completed |
NCT01992900 -
A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria
|
Phase 2 | |
Completed |
NCT04565184 -
Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde
|
Phase 4 | |
Completed |
NCT03896724 -
Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso
|
Phase 1/Phase 2 | |
Completed |
NCT03454048 -
Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2
|
N/A | |
Recruiting |
NCT04844905 -
Adjunctive Ivermectin Mass Drug Administration for Malaria Control
|
Phase 3 | |
Completed |
NCT03138096 -
Safety and Protective Efficacy of Pb(PfCS@UIS4)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04271306 -
Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.
|
Phase 1 | |
Recruiting |
NCT05058885 -
Plasmodium Vivax Among Duffy Negative Population in Cameroon.
|
||
Completed |
NCT04862416 -
Safety and Efficacy of R0.6C Vaccine
|
Phase 1 |